ProfileGDS5678 / 1418656_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 97% 97% 96% 96% 96% 97% 95% 96% 96% 96% 96% 96% 95% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.0739497
GSM967853U87-EV human glioblastoma xenograft - Control 29.4902697
GSM967854U87-EV human glioblastoma xenograft - Control 39.115796
GSM967855U87-EV human glioblastoma xenograft - Control 49.1751396
GSM967856U87-EV human glioblastoma xenograft - Control 59.1603196
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 19.0917297
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.2911495
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.8207296
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.7419596
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.8585296
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.770796
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.9490796
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.4887595
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.1334997